A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)

A platform trial for severely ill patients with COVID-19. It aims to generate evidence that can be applied during the pandemic to reduce mortality, reduce ICU use, and reduce morbidity in severely ill patients with COVID-19 infection.

Imperial PI Professor Anthony Gordon (UK Lead)
Trial Sponsor University Medical Center, Utrecht
Study type Interventional
Study status In recruitment

Find out more about this study here.

Information for study delivery staff at sites          Protocol